Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | CCR2 | P41597 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CCR9 | P51686 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365830 | 0.86 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL28044292 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL700814 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4375589 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4364937 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL6703464 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4539709 | 0.81 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL3817923 | 0.81 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL9536869 | 0.81 | CCR2 (0.76) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4369004 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PIK3C2A | KDM4E 1263/4885ALDH1A1 3904/4885HPGD 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.